FDA Approvals - Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase
Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2 (RedNova)
NEW YORK, Oct. 27 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
Stride Arcolab's standalone net dips by 39% in Q3 (PharmaBiz)
Stride Arcolab suffered heavy setback during the third quarter ended September 2006 due to adverse forex impact, increase in R&D expenditure and lower output at US plant.